AUDITS: Mnemonical Approach for Atrial Fibrillation With Coronary Artery Disease

Published:October 05, 2021DOI:https://doi.org/10.1016/j.nurpra.2021.09.001

      Highlights

      • The mnemonic AUDITS summarized current best evidence to provide a high-yield document for NPs managing patients with atrial fibrillation (AF) in the setting of acute coronary syndrome (ACS).
      • Algorithmic visual guidance is provided on the optimal antithrombotic therapy for nurse practitioners managing patients with AF in the setting of ACS.
      • Use of relevant guidelines in conjunction with clinical judgment is encouraged to ensure patient-centered care and maximize positive outcomes for patients with AF and ACS.

      Abstract

      Managing anticoagulation therapy in patients with acute coronary syndrome and atrial fibrillation requires effective use of risk stratification scores to optimize treatment options while weighing the risk of stroke or systemic thromboembolism vs the risk of bleeding. A mnemonic-based clinical practice pathway is proposed to provide nurse practitioners with a structured approach to managing patients with atrial fibrillation in the context of an acute coronary syndrome. The AUDITS mnemonic represents a simplified treatment guide derived from current guidelines and aims to help nurse practitioners implement best practices to ensure patient safety.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to The Journal for Nurse Practitioners
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Andrade J.G.
        • Aguilar M.
        • Atzema C.
        • et al.
        The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation.
        Can J Cardiol. 2020; 36: 1847-1948https://doi.org/10.1016/j.cjca.2020.09.001
        • Kea B.
        • Manning V.
        • Alligood T.
        • Raitt M.
        A review of the relationship of atrial fibrillation and acute coronary syndrome.
        Curr Emerg Hosp Med Rep. 2016; 4: 107-118https://doi.org/10.1007/s40138-016-0105-2
        • Kumbhani D.J.
        • Cannon C.P.
        • Beavers C.J.
        • et al.
        2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: A report of the American College of Cardiology Solution Set Oversight Committee.
        J Am Coll Cardiol. 2021; 77: 629-658https://doi.org/10.1016/j.jacc.2020.09.011
        • Barstow C.
        • Rice M.S.
        • McDivitt J.D.
        Acute coronary syndrome: diagnostic evaluation.
        Am Fam Physician. 2017; 95: 170-177
        • Norton C.
        Acute coronary syndrome: assessment and management.
        Nurs Stand. 2017; 31: 61-71https://doi.org/10.7748/ns.2017.e10754
        • Nagai M.
        • Itoh T.
        • Ishida M.
        • et al.
        New-onset atrial fibrillation in patients with acute coronary syndrome may be associated with worse prognosis and future heart failure.
        J Arrhythm. 2019; 35: 182-189https://doi.org/10.1002/joa3.12154
        • Lucà F.
        • Caretta G.
        • Vagnarelli F.
        • et al.
        Clinical characteristics, management and outcomes of patients with acute coronary syndrome and atrial fibrillation: real-world data from two nationwide registries in Italy.
        J Cardiovasc Med. 2020; 21: 99-105https://doi.org/10.2459/JCM.0000000000000911
        • Windecker S.
        • Lopes R.D.
        • Massaro T.
        • et al.
        Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome treated medically or with percutaneous coronary intervention or undergoing elective percutaneous coronary intervention: Insights from the AUGUSTUS Trial.
        Circulation. 2019; 140: 1921-1932https://doi.org/10.1161/circulationaha.119.043308
        • Hindricks G.
        • Potpara T.
        • Dagres N.
        • et al.
        2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC [published correction appears in Eur Heart J. 2021;42(5):507] [published correction appears in Eur Heart J. 2021;42(5):546-547] [published correction appears in Eur Heart J. 2021:ehab648.
        Eur Heart J. 2021; 42: 373-498https://doi.org/10.1093/eurheartj/ehaa612
        • Galli M.
        • Andreotti F.
        • D’Amario D.
        Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: a critical appraisal.
        Int J Cardiol Heart Vasc. 2020; 28: 100524https://doi.org/10.1016/j.ijcha.2020.100524
        • Lip G.Y.
        • Collet J.P.
        • Haude M.
        • et al.
        2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA).
        EP Europace. 2018; 21: 192-193https://doi.org/10.1093/europace/euy174
        • Banerjee S.
        • Picheca L.
        CADTH Rapid Response Report: Summary with Critical Appraisal. CHAD65 and CHA2DS2-VASc Risk Stratification Tools for Patients With Atrial Fibrillation: A Review Of Clinical Effectiveness and Guidelines. May 12, 2017.
        (Accessed April 26, 2021)
        • Chou C.Y.
        • Chen Y.Y.
        • Lin Y.J.
        • et al.
        Applying the CHA2DS2-VASc score to predict the risk of future acute coronary syndrome in patients receiving catheter ablation for atrial fibrillation.
        Int J Cardiol Heart Vasc. 2020; 29: 100567https://doi.org/10.1016/j.ijcha.2020.100567
        • Capodanno D.
        • Huber K.
        • Mehran R.
        • et al.
        Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI: JACC state-of-the-art review.
        J Am Coll Cardiol. 2019; 74: 83-99https://doi.org/10.1016/j.jacc.2019.05.016
        • Brown J.D.
        • Goodin A.J.
        • Lip G.Y.
        • Adams V.R.
        Risk stratification for bleeding complications in patients with venous thromboembolism: application of the HAS-BLED bleeding score during the first 6 months of anticoagulant treatment.
        J Am Heart Assoc. 2018; 7e007901https://doi.org/10.1161/JAHA.117.007901
        • Zeng J.
        • Yu P.
        • Cui W.
        • Wang X.
        • Ma J.
        • Zeng C.
        Comparison of HAS-BLED with other risk models for predicting the bleeding risk in anticoagulated patients with atrial fibrillation: a PRISMA-compliant article.
        Medicine. 2020; 99e20782https://doi.org/10.1097/MD.0000000000020782
        • Fanola C.L.
        • Norby F.L.
        • Shah A.M.
        • et al.
        Incident heart failure and long-term risk for venous thromboembolism.
        J Am Coll Cardiol. 2020; 75: 148-158https://doi.org/10.1016/j.jacc.2019.10.058
        • Kotecha D.
        • Chudasama R.
        • Lane D.A.
        • Kirchhof P.
        • Lip G.Y.
        Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes.
        Int J Cardiol. 2016; 203: 660-666https://doi.org/10.1016/j.ijcard.2015.10.220
        • Suwanwongse K.
        • Shabarek N.
        Does atrial fibrillation increase the risk of developing end-stage renal disease in patients with chronic kidney disease?.
        Cureus. 2020; 12e6908https://doi.org/10.7759/cureus.6908
        • Gorenek B.
        • Boriani G.
        • Dan G.A.
        • et al.
        European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRS).
        EP Europace. 2018; 20: 895-896https://doi.org/10.1093/europace/euy051
        • De Rosa S.
        • Sabatino J.
        • Polimeni A.
        • Sorrentino S.
        • Indolfi C.
        Dual anti-thrombotic treatment with direct anticoagulants improves clinical outcomes in patients with atrial fibrillation with ACS or undergoing PCI.
        PLoS One. 2020; 15e0235511https://doi.org/10.1371/journal.pone.0235511
        • Gragnano F.
        • Calabrò P.
        • Valgimigli M.
        Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention?.
        Eur Heart J. 2019; 40: 216-217https://doi.org/10.1093/eurheartj/ehy675
        • Bashore T.M.
        • Granger C.B.
        • Jackson K.P.
        • Patel M.R.
        Acute Myocardial Infarction with ST-Segment Elevation.
        in: Papadakis M.A. McPhee S.J. Rabow M.W. Current Medical Diagnosis & Treatment 2021. McGraw-Hill, 2021: 10-24
        • Sambola A.
        • Rello P.
        • Soriano T.
        • et al.
        Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: a systematic review and meta-analysis.
        Thromb Res. 2020; 195: 128-135https://doi.org/10.1016/j.thromres.2020.07.010
        • Jones D.W.
        • Minhas S.
        • Fierro J.J.
        • et al.
        From WOEST to AUGUSTUS: a review of safety and efficacy of triple versus dual antithrombotic regimens in patients with atrial fibrillation requiring percutaneous coronary intervention for acute coronary syndrome.
        Ann Transl Med. 2019; 7: 405-413https://doi.org/10.21037/atm.2019.08.21
        • Lip G.Y.
        • Banerjee A.
        • Boriani G.
        • et al.
        Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report.
        Chest. 2018; 154: 1121-1201https://doi.org/10.1016/j.chest.2018.07.040
        • Mishra A.
        • Singh M.
        • Acker W.W.
        • et al.
        Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention.
        J Cardiovasc Pharmacol. 2018; 74: 82-90https://doi.org/10.1097/FJC.0000000000000697
        • Angiolillo D.J.
        • Goodman S.G.
        • Bhatt D.L.
        • et al.
        Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention.
        Circulation. 2018; 138: 527-536https://doi.org/10.1161/circulationaha.118.034722
        • Limbruno U.
        • De Sensi F.
        • Cresti A.
        • Picchi A.
        • Lena F.
        • De Caterina R.
        Optimal antithrombotic treatment of patients with atrial fibrillation early after an acute coronary syndrome—triple therapy, dual antithrombotic therapy with an anticoagulant or, rather, temporary dual antiplatelet therapy?.
        J Clin Med. 2020; 9: 2673https://doi.org/10.3390/jcm9082673
        • Fiedler K.A.
        • Maeng M.
        • Mehilli J.
        • et al.
        Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial.
        J Am Coll Cardiol. 2015; 65: 1619-1629https://doi.org/10.1016/j.jacc.2015.02.050
        • Gwyn J.C.
        • Thomas M.R.
        • Kirchhof P.
        Triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a viewpoint.
        Eur Heart J Cardiovasc Pharmacother. 2017; 3: 157-162https://doi.org/10.1093/ehjcvp/pvx002
        • Lopes R.D.
        • Vora A.N.
        • Liaw D.
        • et al.
        An open-label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: rationale and design of the AUGUSTUS trial.
        Am Heart J. 2018; 200: 17-23https://doi.org/10.1016/j.ahj.2018.03.001
        • Yasuda S.
        • Kaikita K.
        • Akao M.
        • et al.
        Antithrombotic therapy for atrial fibrillation with stable coronary disease.
        N Eng J Med. 2019; 381: 1103-1113https://doi.org/10.1056/NEJMoa1904143

      Biography

      Mohamed Toufic El Hussein, PhD, NP, is a professor with the School of Nursing and Midwifery, Mount Royal University, adjunct associate professor, Faculty of Nursing, University of Calgary, and an NP in the division of Cardiology at Alberta Health Services, Rockyview Hospital, Alberta, Canada, and can be contacted at [email protected]

      Biography

      Jenna Habib, BN, RN, ACCN-ER, Emergency Department, Alberta Health Services, Alberta, Canada.